🚀Clinical Research

Spinal Muscular Atrophy: Limits of SMN-Targeted Therapy and Combination Strategies to Protect Muscle and Nerves

Frontiers in human neuroscience·August 13, 2026AI Curation
Spinal Muscular Atrophy: Limits of SMN-Targeted Therapy and Combination Strategies to Protect Muscle and Nerves
✨AI Summary (Beta)Beta

Background

Treatments for spinal muscular atrophy (SMA) have improved survival and motor function, but they do not fully address existing damage or residual disability. A review in Frontiers in Human Neuroscience examines the benefits and limitations of current treatments and summarizes the rationale for combining restoration of deficient survival motor neuron (SMN) protein with strategies to protect muscle and nerves. It does not report new clinical trial results.

SMA is an autosomal recessive genetic disorder in which deletions or loss-of-function variants in both copies of the SMN1 gene cause progressive degeneration of lower motor neurons. The related SMN2 gene also produces functional SMN protein, but its output is limited because exon 7 is usually skipped during RNA processing, or splicing. According to the review, only about 10–15% of SMN2 transcripts include exon 7 and produce full-length protein.

The U.S. Food and Drug Administration (FDA) approved nusinersen in 2016, onasemnogene abeparvovec in 2019, and risdiplam in 2020. The benefits of these treatments were particularly substantial when administered before symptoms appeared. In some patients treated later, however, outcomes were reported to be limited to disease stabilization or incomplete recovery rather than functional improvement.

Key findings

The three drugs share the goal of increasing functional SMN protein levels, but their delivery approaches differ. Nusinersen is an antisense oligonucleotide (ASO) that modifies SMN2 splicing and is administered intrathecally. Onasemnogene abeparvovec is a one-time intravenous treatment that delivers a functional SMN1 gene using an adeno-associated virus serotype 9 (AAV9) vector. Risdiplam is an oral splicing modifier that distributes to central and peripheral tissues.

The authors emphasize that no international standard guidelines yet exist for switching between these drugs. Decisions in practice involve the course of motor function, the burden of repeated intrathecal injections, adverse effects, and patient preferences. Although the drugs’ characteristics can be compared, the optimal switching sequence and washout period have not been established.

Neurofilament light chain (NfL) and compound muscle action potential (CMAP) are discussed as complementary measures for assessing treatment response. NfL reflects axonal injury; reports have described elevated levels in untreated infants with type I SMA that decreased after treatment. CMAP assesses the state of functional motor units electrophysiologically. The review, however, does not provide clinical guidelines for adjusting drug doses in real time according to NfL levels.

Non-SMN targets need to be distinguished by the direction of the intervention and stage of validation. Plastin 3 (PLS3) is a protein that bundles actin filaments; increasing its expression improved neuromuscular junctions and neurotransmission in SMA mice. By contrast, approaches to inhibit neurocalcin delta (NCALD), a calcium-binding protein, have been studied. There is also preclinical evidence that PTEN inhibition improved axon growth and survival in SMN-deficient motor neurons. Within the evidence covered by the review, therapeutic approaches targeting these three proteins had not reached clinical validation in humans.

Implications and outlook

Muscle-targeted strategies also include examples of clinical research. The TOPAZ phase 2 trial described in the review evaluated apitegromab, an antibody that inhibits myostatin activation; improved motor function was reported in patients who received it with nusinersen. This indicates the potential of adjunctive treatments targeting muscle, but it cannot be generalized as proof that all non-SMN combination therapies are effective.

The authors propose making SMN restoration the foundation of treatment while testing additional targets to reduce residual motor disability. Future clinical trials will need to establish the optimal combinations and administration sequence, which patient groups benefit, and long-term safety. Personalized treatment integrating genetic information and biomarkers is also a future concept; it does not mean that genotype-specific combination regimens have been established.

These discussions and levels of evidence can be checked in the full text of the review and the article’s bibliographic information and abstract.

Spinal muscular atrophy (SMA) is a devastating autosomal recessive neuromuscular disorder characterized by progressive degeneration of lower motor neurons, leading to muscle weakness and atrophy predominantly manifesting in childhood. The disease is caused by homozygous deletion or loss-of-function mutations in the survival motor neuron 1 (SMN1) gene, with the nearly identical SMN2 gene acting as a critical modifier of disease severity. Since the initial clinical descriptions in 1891 and the identification of the causative gene in 1995, the field has witnessed transformative therapeutic progress. The FDA approval of nusinersen, an antisense oligonucleotide targeting SMN2 splicing, in 2016 marked the first disease-modifying therapy, followed by the gene replacement therapy onasemnogene abeparvovec in 2019 and the orally administered small-molecule splicing modifier risdiplam in 2020. These SMN-targeted therapies have substantially improved survival and motor outcomes, particularly when administered presymptomatically as enabled by increasingly widespread newborn screening programs. However, a significant proportion of patients, especially those with later-onset disease and adults, show limited responses, and existing therapies cannot reverse established neurodegeneration or muscle pathology. In this review, we trace the history of SMA research and therapy development, critically compare the three approved treatments, and discuss key unresolved challenges including treatment-switching criteria, management of late-diagnosed patients, and the emerging role of biomarkers such as neurofilament light chain and compound muscle action potential. We further explore non-SMN therapeutic strategies targeting PTEN, plastin 3, neurocalcin delta, myostatin, and neuroinflammation, and examine the rationale for combination approaches that integrate SMN restoration with muscle- and neuro-protective agents. Finally, we address future directions encompassing precision medicine, next-gen

💬Why it matters:

This review points to research directions for testing adjunctive approaches in patients who continue to have motor disability after existing SMA treatment. For example, a clinical trial adding a muscle-targeted drug for patients already receiving SMN-targeted treatment could assess changes in motor function and long-term safety together, while identifying which patient groups benefit. The review also provides context for treatment-switch discussions, which should consider the course of motor function alongside the burden of intrathecal injections, adverse effects, and patient preferences. It does not, however, provide clinical guidelines justifying a specific combination regimen or NfL-based dose adjustment. Biomarkers complement clinical assessment, while the optimal combinations and switching procedures still require separate validation.

💬 Comments

0 comments
Please log in to comment
Loading...

BioPlayground

Reading, linking, and lawful quotation stay open; high-speed bulk collection and unauthorized redistribution do not.

Unless stated otherwise, content rights belong to BioPlayground or the relevant rights holder.